Ignite Creation Date:
2025-12-24 @ 9:54 PM
Ignite Modification Date:
2026-02-24 @ 1:15 AM
Study NCT ID:
NCT03054532
Status:
UNKNOWN
Last Update Posted:
2017-02-16
First Post:
2017-02-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
Sponsor:
Singapore General Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2021-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2021-07
Completion Date Type:
ESTIMATED
First Submit Date:
2017-02-13
First Submit QC Date:
None
Study First Post Date:
2017-02-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-02-15
Last Update Post Date:
2017-02-16
Last Update Post Date Type:
ACTUAL